The Université Lille II is a French university for health, sports, management and law. It is located in Lille, Campus Lille II Droit Santé University of Lille II inherits from the Faculty of Law established as the Université de Douai in 1562. Today, science and technologies are taught in an independent campus of Université de Lille I - USTL, while literature and social science are taught as part of the independent campus of Université de Lille III - Charles de Gaulle. Altogether, the universities of Lille include more than 90,000 students and are the core parts of the European Doctoral College Lille-Nord-Pas de Calais that includes 3,000 PhD Doctorate students supported by university research laboratories.Since 1970, the main campus of University de Lille II in situated in Ronchin, in the southern part of Lille.It includes 24 000 students 1050 faculty members and 830 staff 50 research labs, associated to the European Doctoral College Lille Nord-Pas de Calais 250 courses towards nationally-accredited degrees and 170 courses towards university diploma. Wikipedia.
Lille 2 University of Health, Law and Center Hospitalier Regional Et Universitare Of Lille Chru | Date: 2015-06-15
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
Lille 2 University of Health, Law, French Institute of Health, Medical Research and Lille University Hospital Center | Date: 2015-06-11
The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.
Lille University Hospital Center, Lille 2 University of Health, Law and University of the Littoral Opal Coast | Date: 2015-05-12
The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinsons disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its firmation to its administration.
Alzprotect, Lille 2 University of Health and Law | Date: 2016-12-22
The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.
Alzprotect, Lille 2 University of Health and Law | Date: 2014-06-27
The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.
Williams J.,French Institute of Health and Medical Research |
Amouyel P.,French Institute of Health and Medical Research |
Amouyel P.,Lille 2 University of Health and Law |
Amouyel P.,Institute Pasteur Of Lille
Nature Genetics | Year: 2013
Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10-8) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.
Fourrier F.,Lille 2 University of Health and Law
Critical Care Medicine | Year: 2012
It was suggested more than 30 yrs ago that inhibition of the clotting cascade by natural anticoagulants could decrease the high mortality observed in patients suffering from severe sepsis and septic shock. Unfortunately, this therapeutic "paradigm" has led to a dead end, illustrated by the failure of all randomized trials and the recent withdrawal of recombinant activated protein C. Should we now definitely give up trying to treat septic coagulation disturbances or is there any therapeutic alternative? © 2012 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins.
Mathurin P.,Lille 2 University of Health and Law |
Bataller R.,University of North Carolina at Chapel Hill
Journal of Hepatology | Year: 2015
Alcoholic liver disease (ALD) is the most prevalent cause of advanced liver disease in Europe and is the leading cause of death among adults with excessive alcohol consumption. There is a dose-response relationship between the amount of alcohol consumed and the risk of ALD. The relative risk of cirrhosis increases in subjects who consume more than 25 g/day. The burden of alcohol-attributable liver cirrhosis and liver cancer is high and is entirely preventable. Health agencies should develop population-based policies to reduce the prevalence of harmful and/or hazardous alcohol consumption and foster research in this field to provide new diagnostic and therapeutic tools. Disease progression of patients with ALD is heavily influenced by both genetic and environmental factors. Non-invasive methods for the diagnosis of fibrosis have opened new perspectives in the early detection of advanced ALD in asymptomatic patients. Alcoholic hepatitis, the most severe form of ALD, carries a high short-term mortality (around 30-50% at 3 months). Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis but duration of therapy should be adapted to early response. Liver transplantation is the best option for patients with severe liver dysfunction. However, alcohol relapse after transplantation remains a critical issue and drinking habits of transplanted patients need to be routinely screened. © 2015 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
Cousin Biotech, Lille 2 University of Health and Law | Date: 2014-07-09
The invention provides an anastomosis device for joining together hollow lumens or viscera, the device being suitable for being deployed at the surface of two superposed adjacent lumens, said device comprising a main tubular body of longitudinal axis (L), having first and second open ends and opposite outside and inside faces, said main tubular body comprising at least three columns of loops and at least three rows of loops. In characteristic manner, said tubular body further comprises sets of proximal and distal radial projections extending from said tubular body along at least a depth (E) at the peripheries of said first and second ends respectively, said distal and proximal sets being spaced apart by a minimum internal distance (D), and further comprises a set of intermediate radial projections extending from said body along at most a depth (e) and arranged between the sets of proximal and distal radial projections, in that (e) is less than (E), and in that the minimum internal distance (D) is determined so as to receive two superposed adjacent lumens.
Millet G.,Lille 2 University of Health and Law
Annals of surgery | Year: 2012
The objective was to determine the liver regeneration capacity and morbidity and mortality rates after major hepatectomy for colorectal metastases in patients having undergone bevacizumab-based chemotherapy (bev+). Between 2006 and 2011, 41 patients underwent major hepatectomy within 3 months of bevacizumab and were matched with 41 patients operated on following systemic chemotherapy without bevacizumab (bev-). The matching criteria were the following: number of courses of chemotherapy, chemotherapy-free interval, age, and type of hepatectomy. After measurements of remnant liver volume (RLV) preoperatively and at 1 month (RLV1M), volumetric gain was calculated as absolute (RLV1M-RLV) or relative regeneration [(RLV1M-RLV/RLV)]. Ninety-day morbidity was rated according to the Clavien-Dindo classification. There were 21 right, 9 extended right, and 11 left hepatectomies in each group. Groups were comparable in terms of matching criteria, body mass index, American Society of Anesthesiologists score, and RLV. No mortalities were observed. There were no intergroup differences in overall morbidity (56% in bev+ vs 34.1%; P = 0.075) or postoperative liver failure. A severe complication occurred in 5 bev+ (4 eviscerations) and 4 bev- (bile leakages) (P = 0.95). The median hospital stay was similar in both groups as were the degrees of absolute and relative liver regeneration (143% in bev+ vs 114%; P = 0.20). Liver regeneration was not influenced by the type of hepatectomy, the number of courses of chemotherapy, or age more than 65 years. In a methodologically robust trial in the largest cohort reported up to date, bevacizumab did not impair liver regeneration after major hepatectomy-even in elderly patients or those with high exposure to chemotherapy.